Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma

被引：0

作者：

Lian, Bin ^{[1
]}

Mao, Li Li ^{[1
]}

Cui, Chuan Liang ^{[1
]}

Chi, Zhi Hong ^{[1
]}

Si, Lu ^{[1
]}

Sheng, Xi Nan ^{[1
]}

Li, Si Ming ^{[1
]}

Tang, Bi Xia ^{[1
]}

Guo, Jun ^{[1
]}

机构：

[1] Peking Univ, Canc Hosp & Inst, Beijing 100871, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8506

引用

页数：1

共 50 条

[1] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
Pectasides, Dimitrios
Dafni, Urania
Bafaloukos, Dimitrios
Skarlos, Dimosthenis
Polyzos, Aristidis
Tsoutsos, Dimosthenis
Kalofonos, Haralambos
Fountzilas, George
Panagiotou, Petros
Kokkalis, George
Papadopoulos, Othon
Castana, Ourania
Papadopoulos, Stefanos
Stavrinidis, Elias
Vourli, Georgia
Ioannovich, John
Gogas, Helen
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 939 - 944
[2] A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma
Gogas, H.
Dafni, U.
Bafaloukos, D.
Polyzos, A.
Kokkalis, G.
Kalofonos, H. P.
Fountzilas, G.
Skarlos, D.
Tsoutsos, D.
Pectasides, D.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[3] Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
Jonasch, E
Kumar, UN
Linette, GP
Hodi, FS
Soiffer, RJ
Ryan, BF
Sober, AJ
Mihm, MC
Tsao, H
Langley, RG
Cosimi, BA
Gadd, MA
Tanabe, KK
Souba, W
Haynes, HA
Barnhill, R
Osteen, R
Haluska, FG
CANCER JOURNAL, 2000, 6 (03): : 139 - 145
[4] Toripalimab (anti-PD-1) versus high-dose interferon-a2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial
Lian, B.
Si, L.
Chi, Z. H.
Sheng, X. N.
Kong, Y.
Wang, X.
Tian, H.
Li, K.
Mao, L. L.
Bai, X.
Tang, B. X.
Yan, X. Q.
Li, S. M.
Zhou, L.
Dai, J.
Tang, X. W.
Ran, F. W.
Yao, S.
Guo, J.
Cui, C. L.
ANNALS OF ONCOLOGY, 2022, 33 (10) : 1061 - 1070
[5] Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma
Mitchell, Malcolm S.
Abrams, Judith
Thompson, John A.
Kashani-Sabet, Mohammed
DeConti, Ronald C.
Hwu, Wen-Jen
Atkins, Michael B.
Whitman, Eric
Ernstoff, Marc S.
Haluska, Frank G.
Jakowatz, James G.
Das Gupta, Tapas K.
Richards, Jon M.
Samlowski, Wolfram E.
Costanzi, John J.
Aronson, Frederick R.
Deisseroth, Albert B.
Dudek, Arkadiusz Z.
Jones, Vicky E.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 2078 - 2085
[6] A randomized phase II trial of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in high-risk acral melanoma patients.
Si, L.
Mao, L. L.
Chi, Z. H.
Cui, C. L.
Sheng, X. N.
Li, S. M.
Tang, B. X.
Guo, J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[7] Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma
Agarwala, Sanjiv S.
Gray, Robert J.
Wong, Michael K. K.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : E82 - E83
[8] The role of interferon alfa-2b adjuvant therapy of high risk resected melanoma stage I & II.
Economou, GK
Koletsis, EN
Filopoulos, E
PROCEEDINGS EUROSURGERY 2000, 2000, : 141 - 144
[9] Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma Reply
Pectasides, Dimitrios
Dafni, Urania
Gogas, Helen
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : E84 - E84
[10] Quality of Life in Patients Receiving High-Dose Interferon Alfa-2b After Resected High-Risk Melanoma
Mohr, Peter
Hauschild, Axel
Trefzer, Uwe
Weichenthal, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) : E70 - E70

← 1 2 3 4 5 →